Parvez Mantry, MD, shares real-world resmetirom data from AASLD 2026, including GLP-1 combination use and biopsy-sparing monitoring.
|Articles|March 28, 2011
HIT Press Club AJMC - Audience Q&A Session with the Panelists
Author(s)Sachin Jain, MD, MBA
The Q&A Session from the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.
Advertisement
The Q&A Session from the Healthcare Innovations and HIT Q&A Session at the National Press Club in Washington, DC.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
5